Communication, Immunity and Immunization

IOnctura Awarded UK’s MHRA Innovation Passport For Entry ILAP

LifeProNow

MARCH 29, 2023

Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumor proliferation and breaks immune tolerance in patients with solid and hematological tumors. ” [link] The post IOnctura Awarded UK’s MHRA Innovation Passport For Entry ILAP appeared first on LifeProNow.

Immunization

Researchers discovered a cancer mechanism that can eliminate tumors - even those resistant to immunotherapy

World Pharma News

OCTOBER 31, 2024

A technological breakthrough by medical researchers at Tel Aviv University enabled the discovery of a cancer mechanism that prevents the immune system from attacking tumors. The paper was published in the leading journal Nature Communications. Carmit Levy, Prof.

Immunization

Aptar and Healint announce collaboration on CNS and immune system conditions management

Pharmafile

APRIL 24, 2023

AI healthcare company Healint and Software as a Medical Device (SaMD) expert Aptar Digital Health have announced a collaboration aiming to improve central nervous system (CNS) and immune system conditions management. read more

Immunity

Immunity Immunization Communication

After a Vaccine – What? The Shift from Research and Discovery to Communications

Eye on FDA

SEPTEMBER 10, 2020

It is those folks in the middle who are the most important to communicate with. With respect to the latter, the article points out that to achieve the societal aim of ending the pandemic, then uptake will have to be strong to achieve the goal of herd immunity, even when combined with the huge numbers of people who have already been infected.

Communication

Communication Vaccines Immunization Immunity

High levels of exposure to COVID virus may reduce protection from vaccination, prior infection: Study

Express Pharma

AUGUST 23, 2023

The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.

Vaccines

Vaccines Documentation Immunization Immunity

IIL develops needle-free intranasal COVID-19 booster vaccine

Express Pharma

AUGUST 27, 2024

The research on this vaccine was published in the journal Nature Communications on August 26, 2024. The vaccine was created using codon deoptimization technology in collaboration with Griffith University, Australia. The danger due to COVID-19 is still not over. It is still killing around 1,700 people a week around the world.

Vaccines

New antibody could be promising cancer treatment

World Pharma News

NOVEMBER 11, 2024

The study has been published in Nature Communications. Researchers have developed a unique type of antibody that both targets and delivers a drug package via the antibody itself, while simultaneously activating the immune system ("3-in-1 design") for personalised immunotherapy treatments.

Packaging

Packaging Communication Immunization Immunity

Large UK study suggests vaccination helps treat long COVID

pharmaphorum

MAY 19, 2022

They speculate that vaccination may “reset” immunity in people with long COVID who are thought to develop dysregulation of the immune system, similar to an autoimmune condition.

Vaccines

As the Prospect of a Vaccine Approaches, Business and Communications Challenges Are Just Around the Corner

Eye on FDA

NOVEMBER 17, 2020

Vaccination for COVID-19 not only requires business planning, but communications planning in support of the decisions. A post-vaccine environment is going to demand business plans and external and internal communications plans that support and consider multiple scenarios and contingencies.

Communication

Communication Vaccines HIPAA Documentation

Ariceum and UCB to seek therapies for immune-related diseases and cancer

Pharmaceutical Technology

MAY 11, 2023

Ariceum Therapeutics has entered into an exclusive strategic research collaboration agreement with UCB to discover and develop new systemic targeted radiopharmaceuticals to treat immune-related diseases and solid tumours. Please check your email to download the Whitepaper.

Immunization

Immunization Immunity Labelling Communication

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

MARCH 20, 2023

The collaboration, under a sponsored research agreement, will focus on mRNA vaccines that can help in modulating the normal immune response of the body for the treatment of certain autoimmune diseases as well as allergic conditions. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines

Health Innovators: PureTech Health’s Daphne Zohar

pharmaphorum

AUGUST 17, 2021

They discuss the publicly-listed biotech’s pipeline projects and focus on the BIG (brain-immune-gut) axis as well as PureTech’s interest in digital therapeutics. In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health.

Communication

Ultomiris for generalised myasthenia gravis

European Pharmaceutical Review

SEPTEMBER 26, 2022

These antibodies bind to signal receptors at the neuromuscular junction (NMJ), ultimately causing the immune system to attack the site. Eventual symptoms include inflammation and a communication breakdown between the muscles and the brain. Moreover, 80 percent of the patient population are AChR antibody-positive.

Immunization

How Do You Become an Anesthesiologist?

Board Vitals - Pharmacist

NOVEMBER 28, 2022

Communication/Professionalism: 5-7% . The OSCE component assesses communication, professionalism, and technical skills related to patient care. USMLE Step 1. Most students take Step 1 at the end of their second year. The following topics are on the USMLE Step 1 : . USMLE Step 2 CK. The USMLE Step 2CK covers the following: .

Medical Schools

Medical Schools Communication Immunization Immunity

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

DECEMBER 8, 2022

Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. In December last year, the first centre in Japan received authorisation to administer the therapy, while six regional hospitals are currently approved to offer this treatment.

Communication

Communication Immunization Immunity Hospitals

Merck discontinues Phase 3 KeyVibe-010 trial

Express Pharma

MAY 13, 2024

A higher rate of discontinuation of all adjuvant therapy by patients in the coformulation arm versus the KEYTRUDA-only arm, primarily due to immune-mediated adverse experiences, rendered it highly unlikely that the trial could achieve a statistically significant improvement in RFS. Data analysis from this study is ongoing.

Communication

FDA grants orphan drug designation to Temferon for glioblastoma multiforme

Pharmafile

MARCH 3, 2023

The FDA has granted Temferon an Orphan Drug Designation (ODD) for use as a therapeutic option for patients with glioblastoma multiforme, says clinical-stage immune-oncology company Genenta Science in an announcement. read more

Immunization

FDA Places Arbutus’ Chronic Hepatitis B Virus IND Candidate Under Clinical Hold

Pharma Leaders

APRIL 27, 2023

AB-101 is an oral PD-L1 inhibitor candidate intended to boost the immune system of patients by activating and reinvigorating specific T-cells and could, in combination with other drugs, “potentially lead to a functional cure in HBV,” the company said.

Communication

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

JANUARY 10, 2023

These therapies work by reprogramming the immune system, preventing it from attacking and eradicating insulin-producing cells in the pancreas. Equity in early-stage testing. The post Provention’s Tzield can delay type 1 diabetes. But will it reach all patients? appeared first on Pharmaceutical Technology.

Diabetes

Diabetes Immunization Immunity Communication

Can You Answer These 4 USMLE Step 1 Practice Questions?

Board Vitals - Pharmacist

OCTOBER 23, 2024

His mother reports that he has not had any immunizations since 4 months of age. He was seen by his pediatrician 5 weeks ago for low grade fever, cough and runny nose. The coughing spells last for several minutes and are frequently associated with post-tussive emesis. His vital signs are normal and physical examination is unremarkable.

Medical Schools

Medical Schools Compounding Immunization Immunity

Pfizer/BioNTech say COVID-19 vaccine works against UK variant

pharmaphorum

JANUARY 20, 2021

That is good news, but a less encouraging study has just been reported by South African researchers that the variant that was first discovered in their country – known as 501Y.V2 – does exhibit mutations that could make it evade immunity from a prior coronavirus infection.

Vaccines

Vaccines Communication Immunization Immunity

Hospital Universitario and Josep Carreras develop cell therapy for leukaemia

Pharmaceutical Technology

JANUARY 17, 2023

CAR-T therapies are based on the patient’s immune cell modification and can express artificial chimeric receptors that can identify and remove tumour cells. This therapy is expected to be an improvement over CAR-T in relapsed patients, especially those who have less number of normal T lymphocytes.

Hospitals

Hospitals Chemotherapy Communication Immunization

Scientists and medics turn to TikTok to reassure public on vaccine safety

pharmaphorum

DECEMBER 17, 2020

The social media platform, which allows users to share short and often frivolous video clips, has a growing number of experts using it to communicate important information to a broad audience, and particular teenagers and young adults. She told the BBC that her approach on TikTok is “come for the entertainment, but stay for the science.”

Vaccines

Vaccines Communication Immunization Immunity

NICE recommends two CAR T treatments for blood cancers to the Cancer Drugs Fund

Pharmafile

APRIL 27, 2023

Chimeric antigen receptor (CAR T) therapy takes the patient’s own immune system cells ‒ T-cells ‒ and alters them in the lab to attach to and kill cancer cells. Both recommended CAR T therapies are one-off treatments introduced to the patient’s bloodstream. read more

Immunization

AstraZeneca’s NMOSD treatment recommended marketing authorisation by CHMP

Pharmafile

APRIL 3, 2023

Ultomiris is a C5 complement inhibitor which inhibits the C5 protein in the terminal complement cascade ‒ part of the body’s immune system. The complement cascade over-responds in NMOSD patients, which leads to the body to attack its own healthy cells. read more

Immunization

Cell BioEngines announces exclusive licencing agreement for cancer cure

Pharmafile

JANUARY 26, 2023

US-based cell and gene therapy company Cell BioEngines has announced its exclusive licencing agreement with Icahn School of Medicine at Mount Sinai in New York, US, for the development and worldwide commercialisation rights for differentiating most potent immune cells from stem cells and large-scale manufacturing. read more

Immunization

FDA approves Apellis’ geographic atrophy treatment

Pharmafile

FEBRUARY 20, 2023

The drug aims to control the complement cascade, part of the immune system, by targeting C3. Syfovre is claimed to be the first treatment to be approved for GA and offers dose flexibility for patients and physicians with a schedule of every 25 to 60 days. read more

Immunization

FDA pulls approval of COVID-19 antibody treatment due to inefficacy against variants

Pharmafile

JANUARY 27, 2023

The antibody treatment was previously used as an additional layer of protection against the virus for those with compromised immune systems, such as those undergoing chemotherapy, or organ-transplant patients. read more

Chemotherapy

Chemotherapy Immunization Immunity Communication

COVID-19: Helping to support momentum on antimicrobial innovation

pharmaphorum

NOVEMBER 18, 2020

NovaBiotics is proud to be developing antifungal and antiviral therapies alongside antibacterials, all of which mitigate resistance as they are based on platforms engineered from innate immune effector molecules – harnessing the way the body fights disease versus ‘synthetic’ approaches that introduce new resistance pressure to microbes.

Communication

Communication Immunization Immunity Drug Development

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

DECEMBER 21, 2020

To fully realize the potential of these transformative technologies, there needs to be a deep understanding of the communication needs – both educational and promotional – that healthcare systems will face with their introduction. Here are 5 considerations when developing a communications strategy for a novel genetic medicine. #1.

Communication

Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication

Pharmaceutical Technology

JUNE 8, 2023

According to the US-based company, the results demonstrate that Gritstone’s samRNA vaccine candidate boosted immunity for at least 6 months in previously vaccinated older adults. These are generally consistent with initial results from a separate Phase I study in previously unvaccinated subjects (CORAL-CEPI).

Vaccines

Boehringer Ingelheim partners with 3T Biosciences for cancer therapies

Pharmaceutical Technology

JANUARY 10, 2023

The collaboration will combine 3T Biosciences’ 3T- T-Cell Receptor Antigen and Cross-Reactivity Engine (TRACE) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining compounds that are directed towards cancer cells and target immune cells.

Immunization

Immunization Immunity Compounding Communication

argenx enrols new cohort in Phase II multifocal motor neuropathy study

Pharmaceutical Technology

JUNE 20, 2023

The only MMN therapies currently available are immune globulin, with many pipeline therapies being the same. But argenx claims that this leaves a gap in the market since patients receiving immune globulin often still experience disease progression. Please check your email to download the Report.

Immunization

Recap of the NHC’s Annual Membership Meeting and Luncheon & New Board Announced

Putting Patients First Blog

DECEMBER 18, 2023

Recap of the NHC’s Annual Membership Meeting and Luncheon & New Board Announced December 18, 2023 By: Bhriana Onuoha, Senior Coordinator, Communications On Dec. 12, 2023, the National Health Council (NHC) hosted its 103 rd Annual Membership Meeting and Luncheon.

Communication

Communication Diabetes Immunization Immunity

Inaugural Roundtable Explores the Intersection of Federal and State Health Policy

Putting Patients First Blog

MARCH 30, 2023

The panelists discussed a range of topics including managing grassroots, prioritizing resources, sharing research and information, and communicating issues between the state and federal decision makers.

Immunization

Novo Nordisk and Aspect join forces for bioprinting tissue therapeutics

Pharmaceutical Technology

APRIL 12, 2023

According to Aspect’s website, the company’s platform produces tissue therapeutics that are designed to be “biologically functional, immune-protective and suitable for surgical implantation”. The company is developing therapeutic platforms for the liver and the pancreas. Please check your email to download the Report.

Diabetes

Diabetes Immunization Immunity Communication

How digital pathways are changing healthcare

pharmaphorum

JULY 9, 2021

That’s according to Dr Gareth Parkes – a full-time gastroenterologist who co-founded Ampersand Health, which develops digital therapeutics for inflammatory bowel disease (IBD) and other immune mediated inflammatory diseases (IMIDs). Digital therapeutics in practice. About Ampersand Health.

Hospitals

Hospitals Communication Immunization Immunity

NICE recommends Kite’s CAR-T therapy to treat lymphoma

Pharmaceutical Technology

JANUARY 27, 2023

It takes own immune cells of a patient and modifies them to attach and destroy cancer cells. The new CAR-T therapy will be given as a one-off intravenous infusion. Previously, it was available through the Cancer Drugs Fund (CDF). The post NICE recommends Kite’s CAR-T therapy to treat lymphoma appeared first on Pharmaceutical Technology.

Communication